U.S. Markets closed

STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?

Zacks Equity Research

On Feb 09, we issued an updated research report on Ohio-based STERIS plc STE – a manufacturer and marketer of infection prevention, decontamination, microbial reduction, along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #4 (Sell).

STERIS ended third-quarter fiscal 2017 on a dismal note, with earnings and revenues both missing the Zacks Consensus Estimate. The company’s lowered revenue and earnings guidance for fiscal 2017 hints a gloomy operating scenario in the days ahead. Consequently, the company’s share price, which trended above the Zacks Categorized Medical - Instruments industry over the last three months, has nosedived and is currently trading significantly below the broader industry. The stock has gained 2.77% which is much below the 5.38% gain of the broader industry.  

STERIS PLC Price

STERIS PLC Price | STERIS PLC Quote

We note that, the government’s and insurance companies’ consistent efforts to curb the rising healthcare costs have been putting pressure on the stock for quite some time. We are also concerned about the current customer consolidation scenario which will continue to adversely impact the company, unless checked immediately. The competitive landscape and weak cost reduction initiatives also remain an overhang.

On a positive note, organic growth performance was strong across most of the segments. Further, growth in free cash flow reserve is indicative of the strong cash balance reserve the company currently holds.

We note that, Synergy Health – the company STERIS acquired last year, was one of the primary contributors to the strong double-digit revenue growth observed by the combined company. Going ahead, management expects Synergy to contribute between $640–$650 million or a low-single-digit growth in fiscal 2017.

Key Picks

Better-ranked medical stocks include Glaukos Corporation GKOS, Cardiovascular Systems CSII and Neogen Corp. NEOG. Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Glaukos gained over 100% in the last one year  compared with the S&P 500’s gain of 26.2%. The company has a stellar four-quarter average earnings surprise of over 100%.

Cardiovascular Systems surged over 100% in the last one year compared with the S&P 500. It has a four-quarter average earnings surprise of 67.8%.

Neogen gained 37.8% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared with the industry average of 15.2%.

Zacks’ Best Private Investment Ideas

In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?

Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neogen Corporation (NEOG): Free Stock Analysis Report
 
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
 
STERIS PLC (STE): Free Stock Analysis Report
 
Glaukos Corporation (GKOS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research